medrxiv | Background: 2019 Novel coronavirus disease (COVID−19) is turning into a
pandemic globally lately. Angiotensin-converting enzyme 2 (ACE2) is
identified as an important functional receptor for SARS−Cov−2. ACE2 and
ACE are homologues with inverse functions in the renin−angiotensin
system. ACE converts angiotensin I into a vital vasoactive peptide
called angiotensin II(AngII), whereas ACE2 hydrolyzes AngII into a
series of vasodilators. There were few reports illustrated the
expression of AngII in COVID−19. This study aimed to demonstrate the
expression of angiotensin II in COVID−19 and how it correlated to the
disease.
Methods: We enrolled 55 patients with COVID−19 admitted to renmin
Hospital of Wuhan University from January 21st to February 21st, 2020.
Demographic data were collected upon admission. COVID−19 nuclear acid,
plasma AngII, Renin and aldosterone in the lying position without sodium
restriction, and other laboratory indicators were together measured by
the laboratory department of our hospital.
Findings: Of the 55 patients with COVID−19, 34(61.8%) had an increased
level of AngII. The severity of COVID−19 and male is positively related
with the level of AngII. The level of blood lymphocyte, PCT, ALT, and
AST were remarkably severe with those of normal level of AngII (P <
0.05). CD4/CD8 cells ratio was significantly higher whereas CD3+CD8+
cells amount, CD3+CD8+ cells proportion, CD56+CD16+CD3- cells amount and
CD19+CD3- cells amount were considerably lower than those of normal
level of AngII (P < 0.05). Abnormal rates of blood lymphocyte and PCT
were significantly higher in Patients with elevated AngII level. The
results of binary logistic regression analysis showed that the severity
of COVID−19 (OR=4.123) and CD4/CD8 ratio(OR=4.050) were the
co-directional impact factor while female(OR=0.146) was inverse impact
factor of elevated AngII level.
Interpretation: High rate of increased level of AngII was detected in
COVID−19 patients. Patients with elevated AngII level were more likely
to be critically ill with COVID−19. Considering the gender differences
in ACE2 expression and no gender differences in angiotensin expression,
the gender differences in AngII level might indicate less loss of ACE2
in female patients. Elevated AngII level was correlated with CD4/CD8
ratio, suggesting it might involve in immune disorder.
Keywords: 2019 Novel coronavirus disease(COVID−19),
Angiotensin-converting enzyme 2 (ACE2), Angiotensin II(AngII), gender
differences
0 comments:
Post a Comment